Efficacy of paricalcitol in maintenance hemodialysis patients with secondary hyperparathyroidism

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054241

Enrollment

Unknown

Registered

2021-12-11

Start date

2019-12-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism

Interventions

Paricalcitol group:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. MHD patients with SHPT, iPTH > 300pg/ml; 2. Dialysis aged >= 6 months; 3. Calcitriol (use calcitriol for at least 6 months but iPTH is still > 300pg/mL) or calcimimetic is ineffective (use maximum dose of cinacalcet for 2 months but iPTH has not decreased); 4. The patient has discontinued calcitriol or cinacalcet for > 2 weeks.

Exclusion criteria

Exclusion criteria: 1. Parathyroid diseases such as parathyroid adenoma or parathyroid carcinoma; 2. Parathyroidectomy; 3. Patients were reluctant to receive paricalcitol treatment; 4. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
serum calcium;phosphorus;intact parathyroid hormone;alkaline phosphatase;	—

Countries

China

Contacts

Public ContactXue Hen

Ya'an Hospital, West China Hospital of Sichuan

445960797@qq.com+86 13551595279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026